Navigation Links
Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results
Date:5/9/2011

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the first quarter ended March 31, 2011.

"Results from our recently completed Phase 2b study of lesinurad in combination with allopurinol demonstrate lesinurad's potential to bring relief to millions of patients currently suffering with gout," commented Barry D. Quart, PharmD, Ardea's president and chief executive officer.  "We look forward to presenting additional results from this study at the Annual European Congress of Rheumatology in May and discussing our plans for Phase 3 with the Food and Drug Administration in the third quarter."

Recent Accomplishments and Important Upcoming Events

  • In January 2011, we announced positive, topline results from a Phase 2b study (Study 203) adding lesinurad to allopurinol in 208 allopurinol-refractory patients.  At the highest lesinurad dose tested in this study, the number of patients taking the combination who achieved the medically recommended target of below 6 mg/dL was more than three times the number of patients who achieved the target on allopurinol alone.  This translated into an overall response rate of 89 percent using a "last observation carried forward", or LOCF, analysis.  The combination of lesinurad and allopurinol was also well tolerated.
  • In February 2011, we completed an underwritten public offering of approximately 3.2 million shares of our common stock, including the full exercise of an overallotment option granted to the underwriters.  Net proceeds from the sale of the shares, after deducting underwriting discounts and commissions and offering expenses, were approximately $78.1 million.
  • I
    '/>"/>

  • SOURCE Ardea Biosciences, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results
    2. Ardea Biosciences Announces Exercise in Full of Overallotment Option for Common Stock Offering
    3. Ardea Biosciences Prices Public Offering of Common Stock
    4. Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients
    5. Ardea Biosciences to Present at Two Upcoming Investor Conferences
    6. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
    7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
    8. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
    9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
    10. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
    11. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/29/2014)... 2014 Three Lawrence Livermore researchers ... Hydrogen Production R&D Award for their research ... using sunlight. , Shared with collaborators from the ... of Nevada, Las Vegas (UNLV), the award recognizes ... photoelectrochemical solar-hydrogen production and corrosion processes. , These ...
    (Date:8/28/2014)... 2014 Best Sanitizers, Inc., a leader ... processing industry, is asking industry professionals to prepare for ... the E2 soap they’re currently using to the Best ... Hand hygiene is critical to fighting cross-contamination and ... Six key criteria are identified to evaluate the effectiveness ...
    (Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... new market research report is ... Whole Exome Sequencing Market ... Preparation, Target Enrichment), by Services ... Synthesis), by Application (Cancer, Monogenic ...
    (Date:8/28/2014)... MENLO PARK, Calif. , Aug. 28, 2014 ... company focused on developing novel mid- to late-stage ... raised $7.0 million in its first round of ... AshHill Biomedical Investments and Hercules Bioventures with participation ... biotech entrepreneur and pharmaceutical executive, Dr. Larry ...
    Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 3
    ... Overall Survival, Summary: Three ofatumumab Abstracts Have Been Accepted for ... ... Genmab A/S (OMX: GEN),announced today that three ofatumumab (HuMax-CD20(R)) ... of Hematology Annual,Meeting and Exposition (ASH) December 6-9, 2008. Updated ...
    ... Demonstrate No Adverse Toxic Effects, ATLANTA, Nov. ... developing medicines for the treatment of,age-related macular degeneration ... Retina Subspecialty Day at the American Academy of ... was from the ASaP (Assessment,of Safety of Intravitreal ...
    ... at TGH to Enhance Clinical Skills,Development, DENVER, ... new partnership with the University of South Florida ... USF Health hospital,partners and for local and national ... Education Center is located at Tampa,General Hospital, a ...
    Cached Biology Technology:Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 2Genmab A/S: Ofatumumab Pivotal CLL Data to be Presented at ASH 3Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial 2Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial 3Medical Simulation Corporation Announces Partnership With University of South Florida 2Medical Simulation Corporation Announces Partnership With University of South Florida 3
    (Date:8/29/2014)... explored the type and number of connections in transcription ... on robustness in a study published in PLOS ... that the assortativity signature contributes to a network,s resilience ... varying the out-out assortativity of TFN models has a ... other three types of assortativity," said Dov A. Pechenick, ...
    (Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
    (Date:8/28/2014)... that an expansion of marine protected areas is needed ... According to investigators from the Wildlife Conservation Society ... focused on saving the largest numbers of species, often ... and difficult-to-replace ecological functions. , Many vital ... species that also are food for millions of people. ...
    Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
    ... UK scientist has discovered clumps of previously-unreported callus hairs ... and closely-related varieties, which may have storage implications for ... apples is really exciting, says Dr Mary Parker of ... for about as long as human history and Fuji ...
    ... DALLAS March 25, 2008 Researchers at ... $6.5 million grant from the National Institute of ... anti-microbial compound to target bacterial pathogens such as ... drugs are available in the marketplace, new ones ...
    ... humans, are true farmers. The difference is that ants ... Sen Brady at the Smithsonians National Museum of Natural ... issue of the journal Proceedings of the National Academy ... of ants and how these abilities have evolved throughout ...
    Cached Biology News:Popular apple variety harbors unusual cell growth 2NIH awards $6.5 million grant to UT Southwestern to develop new antibiotic 2Smithsonian's National Museum of Natural History reveals ants as fungus farmers 2
    ...
    ...
    ... CpGenome Fast DNA Modification Kit contains reagents ... a DNA sample. In the bisulfite reaction, ... converting them to uracils, while 5-methylcytosines remain ... DNA will differ depending on whether the ...
    ... Gel-Digesting Preparation contains a unique β-agarose digesting ... recovery of intact DNA and RNA from ... electrophoresis in TAE, TBE, MOPS, or phosphate ... in the TAE, TBE, MOPS, and phosphate ...
    Biology Products: